Newsclip®: [Health] FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

"Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.",

0 comments | 1 clip



Last clipped by

Hey! Thanks for checking out Newsclip®!

Click on this Trending Newsclip® Stack to read other top media reports on this topic.

Be sure to clip to your personal newspaper, like, comment and share!

Newsclip® is the leader of Social News Discovery®.

Welcome to the Newsclip® beta release!

Please enjoy the site during our beta phase and provide us with feedback on suggestions and issue details. Please remember that we are still in beta and there will be issues and site changes during this time.

Newsclip® the leading Online Social Newspaper, find trending articles through Social News Discovery®!

Invite Friends to Newsclip®

Invite your Facebook friends to follow you!

You can reopen the "Getting Started Tutorial" dialog from within the About menu in the top right corner.